Loading viewer...
investor_presentation
Format: PDF investor_presentation
A technology company with approximately $700M in annual revenue serving medical and advanced industrial markets. The company generates over $150M in adjusted EBITDA and targets a $6B addressable market growing at 5-7% CAGR, with medical end-markets representing over 50% of revenue.
investor_presentation
18 Pages
investor_presentation
33 Pages
Bank of Georgia Group
Regeneron Pharmaceuticals Investor Presentation — September 2022
investor_presentationinvestor_presentation
42 Pages
Regeneron Pharmaceuticals, Inc.